...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >High-frequency breast ultrasound for the detection of microcalcifications and associated masses in BI-RADS 4a patients.
【24h】

High-frequency breast ultrasound for the detection of microcalcifications and associated masses in BI-RADS 4a patients.

机译:高频乳房超声检查BI-RADS 4a患者的微钙化及相关肿块。

获取原文
获取原文并翻译 | 示例

摘要

AIM: To retrospectively evaluate the diagnostic value of high-frequency ultrasound for the detection of microcalcifications screening in BI-RADS 4a patients. PATIENTS AND METHODS: A total of 52 women (mean age 60.5+/-6.5 years) classified as BI-RADS 4a with microcalcifications, but without associated masses after X-ray mammography (XRM) underwent ultrasound (US) examination (B-mode, ApliPure , and MicroPure imaging). The results were assessed by two independent investigators and analyzed in relation to the B-classification. Written informed consent was obtained before enrolment. RESULTS: The rate of US microcalcification detection was 98.1% (B-mode), 100% (ApliPure) and 25% (MicroPure), respectively. The microcalcification extent was significantly underestimated with all US modalities in comparison with XRM, but the difference was lower for ApliPure as compared to B-mode. ApliPure was also superior in terms of puncture feasibility, facilitating US-guided biopsy in 67.3% as compared to 48.1% (B-mode) and 15.4% (MicroPure). CONCLUSION: In BI-RADS 4a patients, both high-frequency B-mode US and ApliPure imaging are highly sensitive for the detection of microcalcifications, whereas MicroPure ultrasound imaging is unsuitable. ApliPure imaging allowed US guided biopsy for 67.3% of lesions, providing a convenient and economical alternative to stereotactically guided biopsy.
机译:目的:回顾性评估高频超声对BI-RADS 4a患者微钙化筛查的诊断价值。患者与方法:共有52名女性(平均年龄60.5 +/- 6.5岁)被归类为BI-RADS 4a,具有微钙化,但在X线乳房X线照片(XRM)接受超声(US)检查后(B型)无相关肿块,ApliPure和MicroPure成像)。由两名独立研究人员对结果进行了评估,并针对B级分类进行了分析。入学前已获得书面知情同意。结果:美国微钙化检出率分别为98.1%(B型),100%(ApliPure)和25%(MicroPure)。与XRM相比,所有美国模式的微钙化程度均被大大低估,但与B模式相比,ApliPure的差异较小。在穿刺可行性方面,ApliPure也很出色,在美国指导下的活检率仅为67.3%,而B型为48.1%,MicroPure为15.4%。结论:在BI-RADS 4a患者中,高频B型US和ApliPure成像对微钙化的检测高度敏感,而MicroPure超声成像则不合适。 ApliPure成像可在67.3%的病变处进行US引导的活检,从而为立体定向引导的活检提供了方便且经济的替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号